| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3329459 | Critical Reviews in Oncology/Hematology | 2010 | 8 Pages |
ObjectiveMany questions remain unanswered regarding the optimal treatment paradigm for ovarian cancer, and alternatives for both first- and second-line therapy are needed.MethodsThis review summarizes recent data with the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in ovarian cancer.ResultsAnthracyclines are active in ovarian cancer and lack the neurotoxic effects of taxanes. PLD has reduced cardiotoxic potential vs non-liposomal doxorubicin and is the only non-platinum monotherapy to demonstrate a significant survival advantage as second-line treatment of ovarian cancer. Replacing the taxane with PLD in platinum doublets for either first-line or recurrent ovarian cancer (ROC) has been or is being evaluated in more than 1600 patients. Studies evaluating PLD plus carboplatin in platinum-sensitive ROC have shown that the regimen is tolerable and active.ConclusionPLD–carboplatin is a promising chemotherapy combination. Phase III trials will elucidate whether it represents a new standard of care in ovarian cancer.
